NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, JAPAN OR HONG KONG OR WITHIN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD NOT COMPLY WITH APPLICABLE LAWS AND REGULATIONS.
-Immunovia AB (publ) (”Immunovia” or the ”Company”) intends to launch a directed share issue of approximately 2 300 000 of shares.
-Thereafter, the Company, intends to launch a new share issue amounting to approximately SEK 30 million with preferential right for the Company’s existing shareholders.
Immunovia intends to issue approximately 2 300 000 new shares, with deviation from the shareholders preferential right, directed to qualified investors in Sweden and qualified international investors (the “Directed Issue”). If 2 300 000 shares are issued, the new shares will comprise of approximately 14 per cent of the share capital in the Company following the Directed Issue. The Board of Directors may resolve to up-size the Directed Issue with a maximum of 950 000 new shares. The Directed Issue appears to have sprung large attention and Immunovia has already received reservations from anchor investors amounting to approximately SEK 180 million.
The subscription price for the new shares in the Directed Issue is intended to be determined through an accelerated book building process and the shares are to be admitted for trading at Nasdaq First North after they have been issued and registered. The book building process will commence on or about 17.31 CET on 14 September 2016. The board of directors of the Company will thereafter resolve and allot shares in the Directed Issue prior to the opening of Nasdaq First North’s on 15 September 2016.
Payment for shares subscribed for is to be made by cash. The proceeds, together with proceeds received in the new share issue with preferential rights for existing shareholders in accordance with the below, is intended to be used to, amongst other things, facilitate financing of the extended and earlier put activities required to commercialize of IMMrayTM PanCan with in the diabetic group and to achieve a greater geographical market within High risk group 1. A smaller portion of the proceeds (less than 20 per cent) is intended to be used for the purpose to further develop Immunovia’s upcoming test with respect to other cancer forms and for the autoimmune disease Lupus (SLE).
The Directed Issue is subject to a board resolution and the board of directors may cancel the book building process and refrain from launching the Directed Issue or to proceed with the Directed Issue with a higher or lower number of shares than stated above.
Immunovia also intends to issue a new share issue, with preferential right for the existing shareholders of the Company, comprising of a maximum of SEK 30 million (the “Rights Issue”). The board of directors intends to resolve on the Rights Issue and publish further details of the Rights Issue on 15 September 2016. The intention is that the subscription price is to be the same as in the Directed Issue.
Listing on Nasdaq Stockholm
As previously communicated, Immunovia intends to apply for listing of the Company’s shares on Nasdaq Stockholm’s main market during the first half of 2017. Immunovia’s shares are today listed on Nasdaq First North.
Vator Securities AB is financial advisor to Immunovia and Baker & McKenzie Advokatbyrå KB is legal advisor to Vator Securities AB and Immunovia in connection with the Rights Issue.
For further information, contact:
Mats Grahn, CEO Immunovia AB
Phone: +46 (0)70-532 02 30
This information is information that Immunovia AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 17.30 CET on 14 September 2016.
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.
This press release is not an offer or solicitation to acquire shares in Immunovia. A prospectus relating to the Rights Issue referred to in this press release will be filed with the Swedish Financial Supervisory Authority. After approval and registration of the prospectus by the Swedish Financial Supervisory Authority, the prospectus will be published and made available on i.e. Immunovia’s website.
This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. Immunovia does not intend to register any portion of the offering of the securities in the United States or to conduct a public offering of the securities in the United States. The information in this press release may not be announced, published or distributed, directly or indirectly, to the United States, Canada, Australia, New Zealand, Singapore, South Africa, Japan or Hong Kong or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.